Table 2.
Density of D1− or D2 striatal neurons expressing c-fos mRNA after D1 or/and D2 agonists and A2A antagonist, alone or in combination
| Treatment group | n | Fos+/D2− neurons | Fos+/D2+ neurons |
|---|---|---|---|
| Saline (a) | 5 | 34.2 ± 4.6 | 26.7 ± 3.7 |
| Quinelorane (b) | 4 | 5.3 ± 1.7*a | 0.75 ± 0.4*a |
| SKF-82958 (c) | 5 | 84.2 ± 14.8*a | 73.0 ± 10.4*a |
| SCH-58261 (d) | 4 | 22.5 ± 3.8ns,a | 10.8 ± 3.1*a |
| SKF-82958 + quinelorane | 5 | 233.5 ± 25.3*b,c | 22.4 ± 2.5*b,c |
| SKF-82958 + SCH-58261 | 4 | 166.6 ± 18.0*c,d | 65.6 ± 7.7*d,ns,c |
| Quinelorane + SCH-58261 | 5 | 10.8 ± 2.3*b,ns,d | 1.5 ± 0.5*ns,b,d |
Rats were treated with saline (NaCl 0.9%), with the D2 agonist quinelorane (2 mg/kg), with the D1agonist SKF-82958 (1 mg/kg), with the A2A antagonist SCH 58261 (5 mg/kg), or various combinations: SKF-82958 (1 mg/kg) + quinelorane (2 mg/kg), SCH 58261 (5 mg/kg) + SKF-82958 (1 mg/kg), and quinelorane (2 mg/kg) + SCH 58261 (5 mg/kg). c-fos mRNA was detected with double in situ hybridization (exposure times, 10 weeks). Values represent the mean ± SEM of the number ofc-fos mRNA-containing neurons per mm2. Two-way ANOVA, followed by post hoc t tests corrected for the experiment-wise alpha level (Bonferroni correction). The results of the global ANOVA were for quinelorane/SKF-82958 interaction:F(1,15) = 31.55, p < 0.001 for D2-negative neurons and F(1,15) = 4.155 for D2-positive neurons; for SKF-82958/SCH-58261 interaction: F(1,14) = 15.45, p< 0.001 for D2-negative neurons andF(1,14) = 0.35 for D2-positive neurons. For the multiple post hoc t tests Bonferroni correction, an asterisk indicates relevant significant differences between indicated groups (p < 0.05).